Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with gastric juvenile polyposis and SMAD4 mutations are at a high risk of developing gastric cancer; hence, early gastrectomy should be considered.
|
30873576 |
2019 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Smad4/Fascin index is highly prognostic in patients with diffuse type EBV-associated gastric cancer.
|
29572117 |
2018 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The miR-324-3p/Smad4/Wnt signaling axis may be a potential therapeutic target to prevent GC progression.
|
29103082 |
2018 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The frequency of genomic alterations seen in SBA demonstrated distinct differences in comparison with either colorectal cancer (APC: 26.8% [85 of 317] vs 75.9% [4823 of 6353], P < .001; and CDKN2A: 14.5% [46 of 317] vs 2.6% [165 of 6353], P < .001) or gastric carcinoma (KRAS: 53.6% [170 of 317] vs 14.2% [126 of 889], P < .001; APC: 26.8% [85 of 317] vs 7.8% [69 of 889], P < .001; and SMAD4: 17.4% [55 of 317] vs 5.2% [46 of 889], P < .001).
|
28617917 |
2017 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these data demonstrate that miR‑196a‑5p has a key role in EMT and invasion by targeting Smad4 in GCSCs. miR‑196a‑5p may serve as a potential target for gastric cancer therapy.
|
28440445 |
2017 |
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, these findings demonstrate that miR-558 facilitates the progression of gastric cancer through directly targeting the HPSE promoter to attenuate Smad4-mediated repression of HPSE expression.
|
27685626 |
2016 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, EBV-encoded BARF1 promotes cell proliferation in stomach cancer by upregulating NFκB and miR-146a and downregulating SMAD4, thereby contributing to EBV-induced stomach cancer progression.
|
27438138 |
2016 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SB mutagenesis has, thus, helped to catalog the cooperative molecular mechanisms driving SMAD4-induced GC growth and discover genes with potential clinical importance in human GC.
|
27006499 |
2016 |
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SGPP2 and Smad4 at mRNA and protein levels were negatively correlated with miR-31 in human GC tissues and cancer cell lines.
|
26494556 |
2015 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased miR-146a in gastric cancer directly targets SMAD4 and is involved in modulating cell proliferation and apoptosis.
|
22020746 |
2012 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our functional screening uncovers multiple miRNAs that regulate the cellular responsiveness to TGF-β signalling and reveals important roles of miR-199a in gastric cancer by directly targeting Smad4.
|
22821565 |
2012 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that genetic variants in the SMAD4 gene play a protective role in gastric cancer in a Chinese population.
|
21105199 |
2010 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, this study provides a mechanism by which a balance between Smad4 and Smad7 in human gastric cancer is critical for differentiation, metastasis, and apoptosis of tumor cells.
|
19341727 |
2009 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SMAD4 mutation carriers had a significantly higher frequency of gastric polyposis (73%) than did patients with BMPR1A mutations (8%) (p<0.001); all seven cases of gastric cancer occurred in families with SMAD4 mutations.
|
17873119 |
2007 |
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The rate of reduced Smad4 expression was higher in advanced gastric cancer than early gastric cancer.
|
15736060 |
2005 |
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To clarify the clinical significance of TSG expression in gastric carcinoma, the expression of various TSG candidates (p53, E-cadherin, FHIT, smad4, rb, VHL, PTEN, MGMT, p16, and KAI1), as well as other proteins (bcl-2, MUC1, MUC2, MUC5AC, MUC6, CEA, CD44, beta-catenin, C-erbB2, and cyclin B2), was evaluated immunohistochemically in 329 consecutive gastric carcinomas using the tissue array method.
|
12692839 |
2003 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Allelic loss was also noted on chromosome 18q at a marker near Smad4 in this mutated gastric cancer, apparently producing complete inactivation of Smad4 in this tumor.
|
9331080 |
1997 |
Stomach Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Analysis of the DPC4 gene in gastric carcinoma.
|
9197522 |
1997 |